
Harrow, Inc. (NASDAQ:HROW – Free Report) – HC Wainwright raised their FY2026 earnings estimates for shares of Harrow in a research note issued on Wednesday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.40) per share for the year, up from their previous forecast of ($0.57). The consensus estimate for Harrow’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Harrow’s Q2 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.92 EPS and FY2027 earnings at $0.50 EPS.
Harrow (NASDAQ:HROW – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. The company had revenue of $99.30 million during the quarter, compared to analysts’ expectations of $98.59 million.
Check Out Our Latest Report on Harrow
Harrow Trading Up 6.4%
NASDAQ:HROW traded up $1.82 during trading hours on Friday, hitting $30.12. The company had a trading volume of 736,425 shares, compared to its average volume of 697,738. Harrow has a 1 year low of $25.76 and a 1 year high of $54.85. The company has a market cap of $1.13 billion, a P/E ratio of -38.61 and a beta of 0.18. The company has a 50-day moving average of $30.77 and a 200 day moving average of $37.52. The company has a current ratio of 2.29, a quick ratio of 2.08 and a debt-to-equity ratio of 10.15.
Hedge Funds Weigh In On Harrow
A number of institutional investors and hedge funds have recently made changes to their positions in HROW. Marshall Wace LLP lifted its stake in shares of Harrow by 22.1% in the third quarter. Marshall Wace LLP now owns 451,079 shares of the company’s stock valued at $13,893,000 after purchasing an additional 81,644 shares during the period. First Trust Advisors LP grew its position in Harrow by 40.4% during the third quarter. First Trust Advisors LP now owns 140,833 shares of the company’s stock worth $4,338,000 after buying an additional 40,518 shares during the period. Cibc World Market Inc. grew its position in Harrow by 57.1% during the third quarter. Cibc World Market Inc. now owns 13,350 shares of the company’s stock worth $411,000 after buying an additional 4,850 shares during the period. Drive Wealth Management LLC purchased a new position in Harrow in the third quarter valued at about $2,057,000. Finally, Westside Investment Management Inc. increased its holdings in Harrow by 4.7% in the third quarter. Westside Investment Management Inc. now owns 234,526 shares of the company’s stock valued at $7,223,000 after buying an additional 10,475 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.
Recent Harrow Headlines
These are some of the HROW headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.40 from a loss of $0.57, and its Q2 2027 estimate to a loss of $0.10 from a loss of $0.12. The changes suggest some improvement in those periods. Harrow analyst estimate updates
- Positive Sentiment: A recent analysis says HROW still looks undervalued despite a 229% gain over three years, a view that could support investor interest if the valuation argument resonates. Harrow valuation analysis
- Neutral Sentiment: Harrow plans to participate in two investor conferences on November 17 and 18, including a presentation at the Jefferies Global Healthcare Conference. The events may give management a chance to discuss the business, but no new financial information was announced. Harrow investor conference announcement
Harrow Company Profile
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Featured Stories
- Five stocks we like better than Harrow
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
